Готові списки джерел за темами / Distal cholangiocarcinoma

Зміст

Статті в журналах
Дисертації
Частини книг
Тези доповідей конференцій

Добірка наукової літератури з теми "Distal cholangiocarcinoma"

Автор: Grafiati

Опубліковано: 11 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Distal cholangiocarcinoma".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Distal cholangiocarcinoma"

Dickson, Paxton V., and Stephen W. Behrman. "Distal Cholangiocarcinoma." Surgical Clinics of North America 94, no. 2 (April 2014): 325–42. http://dx.doi.org/10.1016/j.suc.2013.12.004.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lad, Neha, and David A. Kooby. "Distal Cholangiocarcinoma." Surgical Oncology Clinics of North America 23, no. 2 (April 2014): 265–87. http://dx.doi.org/10.1016/j.soc.2013.11.001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Liu, Katherine. "Distal cholangiocarcinoma." Journal of Surgical Oncology 95, no. 3 (2007): 192–93. http://dx.doi.org/10.1002/jso.20666.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Serafini, Francesco M., Donald Sachs, Mark Bloomston, Larry C. Carey, Richard C. Karl, Michael M. Murr, and Alexander S. Rosemurgy. "Location, not Staging, of Cholangiocarcinoma Determines the Role for Adjuvant Chemoradiation Therapy." American Surgeon 67, no. 9 (September 2001): 839–44. http://dx.doi.org/10.1177/000313480106700905.

Повний текст джерела

Анотація:

The role of adjuvant chemoradiation therapy (CT/XRT) in the treatment of cholangiocarcinoma is controversial. We undertook this study to determine whether CT/XRT is appropriate after resection of cholangiocarcinomas. One hundred ninety-two patients with cholangiocarcinomas were treated from 1988 to 1999. After resection, patients were assigned a stage (TNM) and were stratified by location of the tumor as intrahepatic, perihilar, and distal tumors. Data are presented as mean ± standard deviation. Of 192 patients 92 (48%) underwent resections of cholangiocarcinomas. Thirty-four patients had liver resections, 25 had bile duct resections, and 33 underwent pancreaticoduodenectomies. Thirty-four patients had adjuvant CT/XRT, three had adjuvant chemotherapy, four had neoadjuvant CT/XRT, and 50 had no radiation or chemotherapy. Mean survival of resected patients with adjuvant CT/XRT was 42 ± 37.0 months and without CT/XRT it was 29 ± 24.5 months ( P = 0.07). Mean survival of patients with distal tumors receiving or not receiving CT/XRT was 41 ± 21.8 versus 25 ± 20.1 months, respectively, ( P = 0.04). Adjuvant chemoradiation improves survival after resection for cholangiocarcinoma ( P = 0.07) particularly in patients undergoing resection for distal tumors ( P = 0.04). Benefits of adjuvant CT/XRT are apparent when stratified by location of cholangiocarcinomas rather than staging.

Стилі APA, Harvard, Vancouver, ISO та ін.

Sallinen, V., J. Sirén, H. Mäkisalo, T. E. Lehtimäki, E. Lantto, A. Kokkola, and A. Nordin. "Differences in Prognostic Factors and Recurrence Patterns After Curative-Intent Resection of Perihilar and Distal Cholangiocarcinomas." Scandinavian Journal of Surgery 109, no. 3 (February 21, 2019): 219–27. http://dx.doi.org/10.1177/1457496919832150.

Повний текст джерела

Анотація:

Background: Perihilar cholangiocarcinoma and distal cholangiocarcinoma arise from the same tissue but require different surgical treatment methods. It remains unclear whether these cholangiocarcinoma types have different outcomes, prognostic factors, and/or recurrence patterns. Methods: This retrospective study evaluated patients who underwent curative-intent resection for perihilar cholangiocarcinoma or distal cholangiocarcinoma at a tertiary academic hospital during 2000–2015. Survival and prognostic factors were identified using Kaplan–Meier and Cox regression analyses. Results: The 90-day mortality rates were 0% for perihilar cholangiocarcinoma (36 patients) and 4% for distal cholangiocarcinoma (47 patients). There were no significant differences between perihilar cholangiocarcinoma or distal cholangiocarcinoma in median overall survival (30.9 vs 40.4 months) or median disease-free survival (14.2 vs 21.4 months). Among perihilar cholangiocarcinoma patients, age > 65 years was an independent predictor of poorer overall survival (hazard ratio: 2.45, 95% confidence interval: 1.07–5.64), while requiring bile duct re-resection was an independent predictor of disease-free survival (hazard ratio: 2.76, 95% confidence interval: 1.01–7.51). Among distal cholangiocarcinoma patients, a pN1 category independently predicted poorer overall survival (hazard ratio: 3.40, 95% confidence interval: 1.14–10.11), while preoperative CA19-9 levels >30 U/mL (hazard ratio: 2.51, 95% confidence interval: 1.09–5.79) and pN1 category (hazard ratio: 2.51, 95% confidence interval: 1.09–5.79) predicted a shorter disease-free survival. Local recurrence was more common with perihilar cholangiocarcinoma (50% of recurrences), while multiple synchronous sites were more common for distal cholangiocarcinoma (41% of recurrences). Conclusion: Perihilar cholangiocarcinoma and distal cholangiocarcinoma patients have similar survival outcomes. However, local control appears to be more prognostic for perihilar cholangiocarcinoma patients, while positive lymph nodes are critical prognostic factor for distal cholangiocarcinoma patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

Xu, Yi. "Treatment of distal cholangiocarcinoma." World Chinese Journal of Digestology 22, no. 28 (2014): 4263. http://dx.doi.org/10.11569/wcjd.v22.i28.4263.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Pandey, Arun, Rajesh Mandal, and Paleswan Joshi Lakhey. "Rare Anomaly of Common Bile Duct in Association with Distal Cholangiocarcinoma." Case Reports in Surgery 2018 (December 17, 2018): 1–3. http://dx.doi.org/10.1155/2018/8351913.

Повний текст джерела

Анотація:

Duplication of common bile duct is a rare entity and its association with distal cholangiocarcinoma is extremely rare. It represents failure of regression of the embryological double biliary system. Here, we describe the diagnostic and therapeutic challenges of a type I variant of the extrahepatic bile duct duplication coexistent with distal cholangiocarcinoma that was diagnosed intraoperatively while treating with Whipple procedure for distal cholangiocarcinoma.

Стилі APA, Harvard, Vancouver, ISO та ін.

Gorji, Leva, and Eliza W. Beal. "Surgical Treatment of Distal Cholangiocarcinoma." Current Oncology 29, no. 9 (September 17, 2022): 6674–87. http://dx.doi.org/10.3390/curroncol29090524.

Повний текст джерела

Анотація:

Distal cholangiocarcinoma (dCCA) is a rare malignancy arising from the epithelial cells of the distal biliary tract and has a poor prognosis. dCCA is often clinically silent and patients commonly present with locally advanced and/or distant disease. For patients identified with early stage, resectable disease, surgical resection with negative margins remains the only curative treatment strategy available. However, despite appropriate treatment and diligent surveillance, risk of recurrence remains high with nearly 50% of patients experiencing recurrence at 5 years subsequent to surgical resection; therefore, it is prudent to continue to optimize neoadjuvant and adjuvant therapies in order to reduce the risk of recurrence and improve overall survival. In this review, we discuss the clinical presentation, workup and surgical treatment of dCCA.

Стилі APA, Harvard, Vancouver, ISO та ін.

Karanjia, Homyar, John A. Abraham, Brian O’Hara, Brandon Shallop, Joseph Daniel, Nicholas Taweel, and Faith A. Schick. "Distal Fibula Metastasis of Cholangiocarcinoma." Journal of Foot and Ankle Surgery 52, no. 5 (September 2013): 659–62. http://dx.doi.org/10.1053/j.jfas.2013.02.017.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Rizzo, Alessandro, and Giovanni Brandi. "Novel Targeted Therapies for Advanced Cholangiocarcinoma." Medicina 57, no. 3 (February 26, 2021): 212. http://dx.doi.org/10.3390/medicina57030212.

Повний текст джерела

Анотація:

Cholangiocarcinoma (CCA) includes a group of rare and aggressive hepatobiliary malignancies, including extrahepatic cholangiocarcinoma (eCCA) and intrahepatic cholangiocarcinoma (iCCA), with the former further subdivided into distal (dCCA) and perihilar cholangiocarcinoma (pCCA) [...]

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Distal cholangiocarcinoma"

Oliveira, Miguel Couto Fernandes de. "Fatores de Prognóstico no Colangiocarcinoma Distal Submetido a Duodenopancreatectomia Cefálica." Master's thesis, 2021. http://hdl.handle.net/10316/98398.

Повний текст джерела

Анотація:

Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina
Introdução: O colangiocarcinoma distal (CCD) é um dos três grandes subtipos de colangiocarcinoma. Trata-se de uma neoplasia com um prognóstico muito reservado, mesmo após resseção curativa. Além disto, pela sua raridade, permanece consideravelmente mal caracterizado. Pretendeu-se caracterizar e avaliar o impacto prognóstico de marcadores clínicos, anatomopatológicos e imuno-histoquímicos em doentes com diagnóstico de CCD submetidos a resseção curativa. Materiais e Métodos: Estudo de coorte retrospetivo, com base numa amostra de 37 doentes com diagnóstico histológico de CCD, submetidos a duodenopancreatectomia cefálica entre 2008 e 2019. Verificou-se uma idade média de 69,19 (±9,92) anos, sendo 62,2% dos doentes do sexo masculino. Além da avaliação clínica e patológica, procedeu-se a avaliação imuno-histoquímica para pesquisa de instabilidade de microssatélites e expressão de HER2, CD44, ALDH1 e CD56. Considerando-se significativos valores de p<0,05, procedeu-se a análise de sobrevivência com recurso a curvas de Kaplan-Meier, comparação dos resultados através do teste de log-rank em análise univariada e regressão de Cox para hazards proporcionais em análise multivariada. Resultados: Com um follow-up mediano de 14±23,7 meses, constatou-se uma sobrevivência global (SG) mediana de 16±2,8 meses e uma sobrevivência livre de doença (SLD) mediana de 14±5,2 meses. Verificou-se expressão de CD44 e ALDH1, respetivamente, em 34,8% e 26,1% dos doentes. Em análise univariada, a resseção de órgãos adjacentes (p=0,010), complicações com grau de Clavien-Dindo igual ou superior a III (GCD≥III) (p=0,003), hemorragia pós-operatória de grau C (HPOGC) (p=0,030), fístula biliar (p<0,001), margens de resseção positivas (MR+) (p=0,006) e a expressão de CD44 (p=0,032) e ALDH1 (p=0,016) tiveram impacto na SG. Com impacto na SLD, verificou-se a incidência de HPOGC (p=0,042), fístula pancreática de grau C (p=0,022) e de deiscência da anastomose gastrojejunal (p=0,042). Em análise multivariada, confirmaram-se como fatores independentes com impacto na SG o GCD≥III (HR=6,64, p=0,042), as MR+ (HR=5,81, p=0,043), e a expressão de CD44 (HR=0,089, p=0,033) e ALDH1 (HR=9,24, p=0,037).Discussão: Além de confirmar o valor prognóstico de marcadores extensamente reconhecidos como tal pela literatura, o estudo demonstra o impacto das complicações pós-operatórias na SG e SLD, bem como a expressão de CD44 e ALDH1 pelo CCD e o seu impacto prognóstico, realçando o importante papel das cancer stem cells no CCD. Conclusão: O presente estudo revelou que GCD≥III, MR+ e a expressão de CD44 e ALDH1 são fatores de prognóstico independentes no CCD. Deverão, portanto, ser considerados na avaliação e estratificação prognóstica dos doentes com CCD submetidos a resseção curativa.
Introduction: Distal cholangiocarcinoma (dCCA) is one of three subtypes of cholangiocarcinoma. It has a dismal prognosis, even after curative resection, as well as a poor characterization owing to its low incidence. The present study sought to evaluate the prognostic value of clinical, pathological and immunohistochemical markers in patients diagnosed with dCCA, after surgical resection.Materials and Methods: A retrospective cohort study was conducted, with a sample of 37 patients with histological diagnosis of dCCA, after undergoing pancreaticoduodenectomy, between 2008 and 2019. The patients had an average age of 69.19 (±9.92) years, being 62.2% of them male. In conjunction with clinical and pathological assessment, immunohistochemical evaluation was carried out to examine the existence of microsatellite instability and expression of HER2, CD44, ALDH1 and CD56. Survival analysis was undertaken with Kaplan-Meier curve analysis, with the results compared with a log-rank test in univariate analysis. A proportional hazards Cox regression was also performed, for multivariate analysis.Results: After a median follow-up of 14±23.7 months, the overall survival (OS) was of 16±2.8 months and the disease free survival (DFS) was of 14±5.2 months. CD44 and ALDH1 expression was observed in 34.8% and 26.1% of the evaluated tumours, respectively. In univariate analysis, adjacent organ resection (p=0.010), a Clavien-Dindo classification ≥ III (CDC≥III) (p=0.003), grade C post-operative haemorrhage (GCPOH) (p=0.030), biliary fistula (p<0.001), positive resection margins (R+) (p=0.006), and CD44 (p=0.032) and ALDH1 (p=0.016) expression were found to influence OS. Additionally, GCPOH (p=0.042), grade C pancreatic fistula (p=0.022) and gastrojejunal fistula (p=0.042) were found to influence DFS. In multivariate analysis, CDC≥III (HR=6.64, p=0.042), R+ (HR=5.81, p=0.043) and CD44 (HR=0.089, p=0.033) and ALDH1 (HR=9.24, p=0.037) expression, were established as independent prognostic factors concerning OS.Discussion: Aside from reinstating the value of prognostic factors extensively recognised as such in literature, the study shows both the impact of post-operative morbidity in OS and DFS, as well as the expression and prognostic value of CD44 and ALDH1 in dCCA, attesting the important role of cancer stem cells in dCCA.Conclusion: The current study shows that CDC≥III, M+ and CD44 and ALDH1 expression have an important influence on OS of dCCA patients. As such, this parameters should be considered in the evaluation and prognostic stratification of patients with dCCA undergoing surgical resection.

Стилі APA, Harvard, Vancouver, ISO та ін.

Elena, Fiorini, Delfino Pietro, D’Agosto Sabrina, Andreani Silvia, Adamo Annalisa, Pezzini Francesco, Frusteri Cristina, et al. "Unraveling the role of lymph node metastasis in PDAC and dCCA progression." Doctoral thesis, 2021. http://hdl.handle.net/11562/1045180.

Повний текст джерела

Анотація:

Tumor progression is characterized by the spread of cancer cells from the primary site to regional lymph nodes and distant organs. In order to colonize distant sites, cancer cells must acquire invasive capacity, while evading elimination by immune cells. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer with the lowest survival rate of all solid tumors. PDAC shares many histological and molecular features with distal cholangiocarcinoma (dCCA), which is a biliary tract cancer usually located in the head of the pancreas albeit showing better prognosis than PDAC. Lymph node metastases (LNM) represent an immunological meeting place for tumor cells and components of the adaptive immunity. Moreover, the pathological N-status (presence and number of LNM) is superior to the T-status (size of the tumor) in predicting survival of PDAC and dCCA patients. However, the biological role of LNM in tumor progression remains undefined. Here, using patient-derived organoids (PDOs) established from matched primary tumor (TP-PDOs) and LNM (LN-PDOs) of 5 patients, we show that both TP- and LN-PDOs shared the histological features and immunophenotypes of parental tissues. Comparative whole-exome sequencing of paired TP- and LN-PDOs showed substantial genetic conservation when considering functional driver genes. Moreover, LN-PDOs did not exhibit increased tumorigenic and/or metastatic capacity in vivo compared to matched TP-PDOs. On the other hand, transcriptional profiles of the cultures showed an overrepresentation of immune-related programs in LN-PDOs and ex vivo experiments demonstrated an elevated immunosuppressive activity of LN-PDOs towards human T lymphocytes. Mechanistically, we found that the mitochondrial form of arginase (ARG2), which catalyzes the hydrolysis of L-arginine to L-ornithine and urea, is overexpressed in LN-PDOs compared to matched TP-PDOs and, accordingly, the addition of exogenous L-arginine partially rescued the suppressive effect of LN-PDOs on T lymphocytes. Taken together, our data show that LNM are able to inhibit T lymphocytes proliferation potentially through arginine depletion, and this may contribute to systemic immunosuppression in these diseases.

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Distal cholangiocarcinoma"

Yokoyama, Yukihiro, Tomoki Ebata, and Masato Nagino. "Surgical Treatment of Distal Cholangiocarcinoma." In The Pancreas, 1083–88. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119188421.ch144.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zimmermann, Arthur. "Extrahepatic Cholangiocarcinoma: Carcinoma of the Middle and Distal Common Bile Duct (Middle and Lower Bile Duct Carcinomas)." In Tumors and Tumor-Like Lesions of the Hepatobiliary Tract, 1–21. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26587-2_28-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zimmermann, Arthur. "Extrahepatic Cholangiocarcinoma: Carcinoma of the Middle and Distal Common Bile Duct (Middle and Lower Bile Duct Carcinomas)." In Tumors and Tumor-Like Lesions of the Hepatobiliary Tract, 527–47. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26956-6_28.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Abdullah Madkhali, Ahmad, and Faisal Al-alem. "Distal Cholangiocarcinoma." In Bile Duct Cancer. IntechOpen, 2019. http://dx.doi.org/10.5772/intechopen.84625.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lee, Christine U., and James F. Glockner. "Case 17.20." In Mayo Clinic Body MRI Case Review, edited by Christine U. Lee and James F. Glockner, 827–28. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199915705.003.0438.

Повний текст джерела

Анотація:

72-year-old man with cholangiocarcinoma in the distal common bile duct VR image from 3D FRFSE MRCP (Figure 17.20.1) demonstrates moderately dilated intrahepatic ducts in the central right hepatic lobe, poorly visualized ducts in the medial left lobe, and dilated ducts in the lateral left lobe. There is an abrupt cutoff of the common bile duct near the pancreatic head, with a stent extending into the duodenum, and an apparent filling defect proximal to the obstruction. Notice also the dilated pancreatic duct. Axial fat-suppressed 3D SSFP images (...

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Distal cholangiocarcinoma"

Kim, Hayeon, Soo Yeon Lee, Aeree Kim, Baek-hui Kim, and Chung-yeul Kim. "Abstract 3627: Comparison of genetic profiles of small and large duct type intrahepatic cholangiocarcinoma with distal extrahepatic cholangiocarcinoma." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3627.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Yagawa, Yohsuke, Atsushi Aruga, Nobuhiro Takeshita, Ryota Higuchi, Takehisa Yazawa, Keishi Tanigawa, and Masakazu Yamamoto. "Abstract 1126: Association of CXCR4 expression with lymph node metastasis in distal cholangiocarcinoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1126.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hahn, F., L. Müller, Y. Tanyildizi, D. Pinto dos Santos, C. Düber, PR Galle, A. Weinmann, R. Kloeckner, and A. Mähringer-Kunz. "Distant metastases in patients with intrahepatic cholangiocarcinoma: Does location matter?" In 36. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3402230.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Savino, M. S., L. Cavinato, G. Costa, F. Fiz, G. Torzilli, L. Vigano, and F. Ieva. "Distant supervision for imaging-based cancer sub-typing in Intrahepatic Cholangiocarcinoma." In 2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). IEEE, 2022. http://dx.doi.org/10.1109/embc48229.2022.9871262.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!